Veeva Systems heads into the back half of 2026 with shorts unwinding at pace, options sentiment near its most optimistic in a year, and the Street divided on whether the stock's 11% weekly rally has already priced in the good news.
The most striking development this week is the scale of the short unwind. Short interest has dropped 14% in a single week to roughly 4.9% of the free float — down from nearly 6.7% at the peak in early June, and a 25% decline over the past month. The retreat has been rapid and consistent, with bears covering throughout June as the stock climbed from the low $160s. What makes this notable is context: shorts were building through May and into the first week of June, right up to and just after Veeva's earnings print. That report triggered a 6% one-day drop on June 17 and the stock subsequently shed another 10% over the following five days. The short-building phase looks like it tracked that weakness precisely — and now the same crowd is exiting.
The borrow market corroborates the easing pressure. Availability is exceptionally loose at roughly 919% — meaning there are nearly nine shares available to lend for every one already borrowed. That's well into normal-to-loose territory and has actually widened over the past week, up around 10%. Cost to borrow barely registers at 0.51%, near its recent floor. There's no squeeze dynamic here, no tightening borrow pool chasing a falling float. The covering looks orderly and fundamentals-driven, not forced. Options positioning reinforces the picture from the other direction. The put/call ratio has dropped to 0.40, almost a full standard deviation below its 20-day average of 0.46, and is near the lowest level of the past year. Investors are not hedging — they're expressing a directional view through calls. The PCR was running above 0.60 in late May when the short position was at its peak; the shift to 0.40 now mirrors the short unwind almost exactly.
The Street is split, but the bullish camp holds the structural argument. The mean analyst price target of around $244 implies roughly 38% upside from the current $177.47 — a wide gap, though it has narrowed from over 60% as the stock has rallied this month. The post-earnings analyst moves in early June were broadly cautious. Goldman Sachs lowered its target to $165 while maintaining a Sell rating. Evercore ISI cut sharply, from $240 to $185 at In-Line. UBS and BMO both trimmed to the $175–$190 range. Bulls, including RBC and Oppenheimer, held firm at $225–$275 and reiterated Outperform. The divide is less about whether Veeva has a durable franchise — it does, anchored in life sciences cloud with strong FCF margins — and more about whether the re-rating after a disappointing quarter has already run its course. ORTEX factor scores show strong near-term EPS momentum (83rd percentile on 30-day), which supports the bull case. The short score of 41.5 has drifted lower all week from 45 last Monday, consistent with the unwinding narrative.
Peers have moved broadly in the same direction. PHR gained 12% on the week, WAY added 11.5%, and TDOC rose 10%. The sector bid appears genuine rather than VEEV-specific. One outlier worth noting: CERT surged 21% over the same period, while DOCS barely moved at +1.3%, suggesting the week's gains were not uniform across health care technology names. Veeva's 11% move sits comfortably in the middle of the peer range.
With the next earnings event not due until August 26, the question over coming weeks is whether the recent short unwind has cleared enough overhang to allow the valuation gap between the current price and analyst targets to close further — or whether the bears who trimmed positions now circle back if growth signals disappoint heading into Q2.
See the live data behind this article on ORTEX.
Open VEEV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
